股票简称：华海药业 股票代码：600521 公告编号：临 2024-096 号 债券简称：华海转债 债券代码：110076 浙江华海药业股份有限公司 关于"华海转债"预计触发转股价格向下修正的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●证券代码：600521，证券简称：华海药业 ●转债代码：110076，转债简称：华海转债 ●转股价格：33.73 元/股 ●转股时间：为 2021 年 5 月 6 日至 2026 年 11 月 1 日 1、修正权限和修正幅度 在可转债存续期间，当公司股票在任意三十个连续交易日中至少十五个交易日 收盘价格低于当期转股价格的 80%时，董事会有权提出转股价格向下修正方案并提 交股东大会表决，该方案须经出席会议股东所持表决权的三分之二以上通过方可实 施。股东大会表决时，持有本次发行可转债的股东应当回避。 修正后的转股价格应不低于该次股东大会召开日前二十个交易日公司股票交易 均价和前一个交易日公司股票交易均价，同时，修正后的转股价格不得低于最近一 期经审计的每股净 ...

重要内容提示： 浙江华海药业股份有限公司（以下简称"公司"）于2024年8月27日召开第 八届董事会第二十七次临时会议，会议审议通过了《关于提议召开公司2024年 第一次临时股东大会的议案》，公司将于2024年9月12日召开2024年第一次临时 股东大会，并已于2024年8月28日在中国证券报、上海证券报、证券时报、证券 日报和上海证券交易所网站www.sse.com.cn上刊登了《浙江华海药业股份有限公 司关于召开2024年第一次临时股东大会的通知》。为进一步保护投资者的合法 权益，为公司股东行使股东大会表决权提供便利，现将有关事项再次提示如下： 一、 召开会议的基本情况 证券代码：600521 证券简称：华海药业 公告编号：临 2024-095 号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 关于召开 2024 年第一次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (一) 股东大会类型和届次 2024 年第一次临时股东大会 1 / 6 股东大会召开日期：2024年9月1 ...

浙江华海药业股份有限公司 股东大会会议议案 浙江华海药业股份有限公司 2024 年第一次临时股东大会资料 股票简称：华海药业 股票代码：600521 中国·浙江·临海 二零二四年九月十二日 浙江华海药业股份有限公司 股东大会会议议案 浙江华海药业股份有限公司 2024 年第一次临时股东大会会议议程 1、审议《关于延长公司向特定对象发行股票股东大会决议有效期及授权有 效期的议案》 2、审议《关于修订公司章程部分条款的议案》 3、审议《关于修订<浙江华海药业股份有限公司对外捐赠与赞助管理制度> 的议案》 四、股东现场提问 五、选举大会计票人、监票人 时间：2024 年 9 月 12 日下午 14 点 30 分 地点：浙江省临海市汛桥浙江华海药业股份有限公司行政楼高级报告厅 会议议程 一、与会者签到 二、大会开始，主持人讲话 三、审议议案 六、投票表决，统计表决结果 七、见证律师宣读会议见证意见 八、会议结束 1 浙江华海药业股份有限公司 股东大会会议议案 浙江华海药业股份有限公司 2024 年第一次临时股东大会现场投票表决办法 一、各项议案的通过，由股东或股东代表以记名方式分别表决。 二、每一表决票分别注明该票所 ...

f 隔证券 医药生物/化学制药 公 司 研 究 华海药业（600521.SH） 2024 年 09 月 03 日 2024 上半年业绩快速增长，国内制剂业务强劲增长 ——公司信息更新报告 投资评级：买入（维持） | --- | --- | |---------------------------|---------------------------| | | | | 余汝意（分析师） | 阮帅（分析师） | | yuruyi@kysec.cn | ruanshuai@kysec.cn | | 证书编号： S0790523070002 | 证书编号： S0790524040007 | 2024 年上半年业绩快速增长，国内制剂业务强劲增长 2024 年上半年公司实现营收 51.28 亿元（同比+19.43%，下文都是同比口径）， 归母净利润 7.49 亿元（+31.6%），扣非归母净利润 7.65 亿元（+18%），毛利率 62.01%（+1.88pct），净利率 14.71%（+1.6pct）。2024 上半年公司原料药中间 体板块较快增长，制剂板块维持较快增长。我们看好公司的长期发展，维持公司 的盈利预测， ...

Investment Rating - The report maintains a "Strong Buy" rating for Huahai Pharmaceutical (600521) with a target price of 26.3 CNY, compared to the current price of 16.83 CNY [1][2]. Core Views - The company achieved record high quarterly performance in Q2 2024, with revenue of 26.30 billion CNY (+17.65%) and net profit of 4.78 billion CNY (+20.67%) [1][2]. - The report highlights a strong recovery in the raw materials segment, with revenue of 18.93 billion CNY (+19.5%) and a gross margin of 49.3% (+5.6 percentage points) in H1 2024 [2]. - The domestic formulation business is a key growth driver, with overall revenue of 31.46 billion CNY (+18.7%) and a gross margin of 69.9% (-0.3 percentage points) in H1 2024 [2]. Financial Summary - Total revenue for 2023 is projected at 8,309 million CNY, with expected growth to 10,546 million CNY in 2024 (+26.9%) [3]. - The net profit for 2023 is estimated at 830 million CNY, with a significant increase to 1,312 million CNY in 2024 (+58.0%) [3]. - Earnings per share (EPS) is expected to rise from 0.57 CNY in 2023 to 0.89 CNY in 2024 [3]. Business Segments - The raw materials segment is expected to continue its growth trajectory, driven by the stabilization of core product prices and expansion into new markets [2]. - The domestic formulation segment is anticipated to grow by 25-30% in 2024, supported by new product launches and market expansion efforts [2]. - The overseas formulation segment remains stable, with revenue from the U.S. market at 720 million CNY, showing no significant change year-on-year [2]. Valuation - The report suggests a valuation premium due to the company's strong growth prospects and leading position in advanced pharmaceutical manufacturing, applying a 30x PE ratio for 2024 [2].

| 证券代码：600521 | 证券简称：华海药业 | 公告编号：临 | 2024-093 | 号 | | --- | --- | --- | --- | --- | | 债券代码：110076 | 债券简称：华海转债 | | | | 浙江华海药业股份有限公司 关于2024年半年度募集资金存放与实际使用情况的专项报告 为了规范募集资金的管理和使用，提高资金使用效率和效益，保护投资者权益， 1 / 6 本公司按照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《上海证券交易所股票上市规则》（以 下简称"股票上市规则"）及《上市公司监管指引第2号——上市公司募集资金管理和 使用的监管要求（2022年修订）》等有关法律、法规和规范性文件的规定，结合公司 实际情况，制定了《浙江华海药业股份有限公司募集资金管理制度》（以下简称"《募 集资金管理制度》"）。公司对募集资金实行专户存储，在银行设立募集资金专户。 1、募集资金管理情况 2020 年 11 月 9 日，公司及全资子公司浙江华海建诚药业有限公司（以下简称"华 海建诚"）、全资子公司浙江华海生物科技有限公司 ...

Financial Performance - The company's operating revenue for the first half of 2024 reached ¥5,128,307,063.04, representing a 19.43% increase compared to ¥4,294,130,016.33 in the same period last year[14]. - Net profit attributable to shareholders of the listed company was ¥748,566,030.81, up 31.60% from ¥568,819,789.73 in the previous year[14]. - The net profit after deducting non-recurring gains and losses was ¥764,852,741.61, an 18.00% increase from ¥648,158,480.43 in the same period last year[14]. - The net cash flow from operating activities was ¥1,297,827,513.80, showing a significant increase of 45.72% compared to ¥890,637,394.62 in the previous year[14]. - Basic earnings per share increased by 33.33% to CNY 0.52 compared to the same period last year[16]. - The company reported a significant increase in revenue, with a year-on-year growth of 15% in the first half of 2024[24]. - The company reported a net profit increase, with undistributed profits reaching ¥8,000,944,455.49, compared to ¥6,746,953,981.87 in the previous year[160]. - The company’s total equity increased to ¥11,830,466,477.12, up from ¥10,615,633,831.34 in the previous year[160]. Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥19,513,444,950.28, a 4.91% increase from ¥18,599,969,612.84 at the end of the previous year[14]. - The net assets attributable to shareholders of the listed company were ¥8,802,460,428.42, reflecting an 8.98% increase from ¥8,076,851,901.19 at the end of the previous year[14]. - The company's total liabilities amounted to 10.549 billion RMB, with current liabilities of 5.713 billion RMB and non-current liabilities of 4.836 billion RMB[152]. - The company's total assets reached CNY 19,513,444,950.28, up from CNY 18,599,969,612.84, indicating a growth of 4.91%[157]. - The total liabilities increased to CNY 10,549,141,204.00, compared to CNY 10,348,854,672.57, marking a rise of 1.93%[157]. Research and Development - The company is focusing on the development of innovative drugs, with over 20 projects currently in clinical research, including 12 in advanced stages[19]. - The company is investing $50 million in R&D for new technologies aimed at enhancing product efficacy and safety[24]. - The company has initiated key clinical trials for its innovative drug HB0034, with 23 patients enrolled as of the report date, targeting Generalized Pustular Psoriasis (GPP)[50]. - The company is focusing on the development of innovative drugs in the fields of autoimmune diseases and oncology, with over 20 projects currently in research[49]. - The company has established advanced technology platforms and an innovative R&D system, with multiple research centers focusing on various drug development areas, including antiviral drugs[37]. Market Expansion and Strategy - The company is actively expanding its global sales network and optimizing its organizational structure to enhance market penetration[16]. - Market expansion plans include entering three new international markets by the end of 2024, targeting a 15% increase in global market share[25]. - The company has completed a strategic acquisition of a competitor, which is projected to increase annual revenue by $100 million[24]. - The company has established a stable partnership with over 1,000 pharmaceutical companies globally, covering nearly 90% of major market clients[18]. - The company is committed to internationalization and has developed a global sales system with recognized production capabilities[31]. Environmental and Compliance - The company has implemented a three-year action plan for safety and environmental management, aiming for high-level safety and sustainable development[52]. - The company has established an environmental management system that complies with national and local regulations for environmental self-monitoring[100]. - The company has successfully passed over 140 GMP audits in the first half of the year, indicating strong compliance and quality management[52]. - The company is committed to sustainable practices, focusing on reducing environmental impact and enhancing safety measures in production processes[72]. - The company has established online monitoring systems at discharge points to ensure compliance with pollution discharge standards[95]. Corporate Governance and Shareholder Information - The company has not disclosed any plans for profit distribution or capital reserve transfer to increase share capital during this reporting period[2]. - The company has not faced any violations in decision-making procedures for providing guarantees[4]. - The company has committed to ensuring the independence of its operations and decision-making as a publicly listed entity[107]. - The total number of shareholders reached 59,045 by the end of the reporting period[137]. - The largest shareholder, Chen Baohua, holds 368,877,935 shares, representing 25.15% of the total shares[138]. Risks and Challenges - The company faces risks related to new product development, including long approval cycles and potential failures in registration, which could adversely affect financial returns[69]. - Fluctuations in raw material prices due to geopolitical tensions and market competition are impacting profitability, prompting the company to diversify its product pipeline[74]. - The company is exposed to foreign exchange risks due to its international operations, particularly with USD transactions, which could affect revenue and profit margins[75]. - Trade environment changes, influenced by geopolitical factors, may pose challenges to the company's export business and overall market access[76]. - The company is adapting to regulatory changes in the pharmaceutical industry, including price control policies and procurement reforms, to mitigate operational risks[73].

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2024-094 | 号 | | --- | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | | 浙江华海药业股份有限公司 关于制剂产品获得美国 FDA 批准文号的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下简称"公司"）向美国食品药品监督管理局 （以下简称"美国 FDA"）申报的甲磺酸沙芬酰胺片的新药简略申请（ANDA，即 美国仿制药申请）获得正式批准，恩格列净片和卡格列净片的新药简略申请获得暂 时批准（暂时批准：指 FDA 已经完成仿制药的所有审评要求，但由于专利权或专 卖权未到期而给予的一种批准形式），现将相关情况公告如下： 一、甲磺酸沙芬酰胺片的相关情况 1、药物名称：甲磺酸沙芬酰胺片 6、申请人：普霖斯通制药有限公司（Prinston Pharmaceutical, Inc.） 7、审批情况：正式批准 甲磺酸沙芬酰胺片主要用于治疗帕金森 ...

浙江华海药业股份有限公司（以下称"公司"）第八届董事会第二十八次临时会 议于二零二四年八月二十九日上午九点在公司四楼会议室以通讯方式召开。会议应 到会董事九人，实际到会董事九名，符合召开董事会会议的法定人数。会议由公司 董事长李宏先生主持。会议程序符合《中华人民共和国公司法》（以下简称"公司法"）、 《中华人民共和国证券法》（以下简称"《证券法》"）及《浙江华海药业股份有限公 司章程》（以下简称"公司章程"）的规定。会议审议并通过了如下决议： 一、审议通过了《公司 2024 年半年度报告全文及其摘要》 表决情况：同意：9 票；反对：0 票；弃权：0 票。 该议案已经公司第八届董事会审计委员会第五次会议审议通过，且已经公司本 次董事会审议通过。 《浙江华海药业股份有限公司 2024 年半年度报告》及其摘要详见公司于 2024 年 8 月 31 日发布在上海证券交易所网站（www.sse.com.cn）上的公告。 二、审议通过了《公司 2024 年半年度募集资金存放与实际使用情况专项报告》 | 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2024-091 | 号 | | --- | -- ...

| 股票代码：600521 | 股票简称：华海药业 | 公告编号：临 | 2024-092 | 号 | | --- | --- | --- | --- | --- | | 债券代码：110076 | 债券简称：华海转债 | | | | 浙江华海药业股份有限公司 第八届监事会第十七次临时会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下称"公司"）第八届监事会第十七次临时会 议于二零二四年八月二十九日在公司四楼会议室以通讯方式召开。会议应到会监 事三人，实际到会监事三人，符合召开监事会会议的法定人数。会议由监事王虎 根先生主持。会议程序符合《中华人民共和国公司法》（以下简称"公司法"）、《中 华人民共和国证券法》（以下简称"《证券法》"）及《浙江华海药业股份有限公司 章程》（以下简称"《公司章程》"）的规定，会议合法有效。会议审议并一致通过 了如下议案： 一、审议通过了《公司 2024 年半年度报告全文及其摘要》 表决情况：同意 3 票； 反对 0 票； 弃权 0 票。 公司监事会 ...